GI-MAP | GI Microbial Assay Plus
Optimal Health — It All Starts with the GI-MAP®
Results You Can Rely On
Why Is Quantification Using qPCR Technology So Important?
Unlike other comprehensive stool tests on the market, the GI-MAP can provide practitioners with truly quantitative results. qPCR offers a much more accurate way to detect and quantify clinically-relevant organisms than standard PCR, culture, microscopy, or DNA sequencing-based methods. Accurately assessing how much of an organism's DNA is present in a patient's stool sample is essential for helping practitioners to determine the clinical significance of pathogenic organisms and dysbiosis patterns.
qPCR's Reliability, Reproducibility, and Use in Clinical Research
Although qPCR is becoming more commonplace in in-vitro diagnostics (IVD), we are the only laboratory in the United States exclusively using qPCR technology for advanced comprehensive stool testing. This technology is used routinely in clinical and academic research because it provides highly-accurate quantification, as well as high levels of sensitivity and specificity. Standard PCR technology doesn't offer the same level of sensitivity, or the ability to express precise numerical results.
The GI-MAP also provides consistently reproducible results. Reproducibility is of crucial importance to the practitioners and patients that rely on the efficacy of the GI-MAP. To achieve it, we perform rigorous quality control, and have validated all molecular target quantification assays to meet or exceed FDA standards.
GI-MAP Allows for the Personalized Treatment Plans and Informative Retests
The GI-MAP's accuracy and reliability allows practitioners to create personalized treatment protocols to address gut dysfunction based on which infections are urgent, which areas of the gut are already optimized, and which areas should be addressed after an infection is resolved.
Additionally, the quantification offers a remarkable ability to see how treatment modalities are working because a retest after treatment can show whether a parasite has resolved, dysbiosis has improved, and more.
Who Should Have the GI-MAP Comprehensive Stool Analysis Done?
Almost every patient can benefit from a GI-MAP gut health assessment. Some patients are looking to achieve optimal health, while other patients have been chronically ill and frustrated without a diagnosis for years.
Some conditions that warrant testing are:
- Autoimmune diseases
- Digestive complaints, diarrhea or constipation
- Brain fog
- Skin problems, like acne and psoriasis
- Mood disorders, depression, and anxiety
- Diabetes and weight loss issues
Can Infants and Children Benefit from the GI-MAP?
Yes. The GI-MAP is commonly used in infants and children, and can provide insight into conditions related to Attentional Deficit Hyperactivity Disorder, Autism, and digestive complaints. Patients – See Ordering Info Below
What is Reported on GI-MAP Test Results?
The Gastrointestinal Microbial Assay Plus (GI-MAP) is an innovative clinical tool that measures gastrointestinal microbiota DNA from a single stool sample with state of the art, quantitative polymerase chain reaction (qPCR) technology.
The GI-MAP was designed to detect microbes that may be disturbing normal microbial balance or contributing to illness as well as indicators of digestion, absorption, inflammation, and immune function.
The following is a listing of the microorganisms found on the GI-MAP by page:
The GI-MAP® includes pathogens (bacterial, parasitic, and viral) commonly known to cause intestinal gastroenteritis. It's important to note that not all individuals with positive findings for pathogens will present with symptoms. Many factors, including the health of the individual, the transient nature of some pathogens, and the presence and expression of virulence factors all contribute to an individual's symptoms.
Toxins are a type of virulence factor produced by certain pathogens. Since GI-MAP is a DNA-based test, results reflect the levels of pathogenic strains carrying the toxin genes, not the levels of any toxins that may be produced.
- C. difficile Toxin A
- C. difficile Toxin B
- Enterohemorrhagic E. coli
- E. coli O157
- Enteroinvasive E. coli/Shigella
- Enterotoxigenic E. coli LT/ST
- Shiga-like Toxin E. coli stx1
- Shiga-like Toxin E. coli stx2
- Vibro cholerae
- Yersinia enterocolitica
- Entamoeba histolytica
- Adrenovirus 40/41
- Norovirus GI
- Norovirus GII
Recent studies have shown that nearly 50% of the world's population may harbor H. pylori. And, although many carriers are asymptomatic, H. pylori is known to have a causative role in ulcers, chronic gastritis, and stomach cancer.
Additionally, in early phases of colonization, patients may experience hypochlorhydria followed by a change to hyper aciduria. Over time, additional H. pylori strains may colonize, including those with Virulence Factors and increased disease potential.
- H. pylori
- Virulence Factor, babA
- Virulence Factor, cabA
- Virulence Factor, cabPAI
- Virulence Factor, dupA
- Virulence Factor, iceA
- Virulence Factor, opiA
- Virulence Factor, vacA
Trillions of microorganisms inhabit the human intestine to make up a complex ecosystem that plays an important role in human health. Commensal bacteria extract nutrients and energy from our diets, maintain gut barrier function, produce vitamins (biotin and vitamin K), and protect against colonization by potential pathogens.
- Akkermansia Mucinophilia
- Bacteroides fragilis
- Bifidobacterium spp.
- Clostridia (class)
- Enterobacter spp.
- Enterococcus spp.
- Escherichia spp.
- Faecalbacterium prausnitzii
- Lactobacillus spp.
- Firmicutes/Bacteroidetes Ratio
Many bacteria measured on the GI-MAP are considered opportunistic pathogens, as they only cause disease and illness in some individuals, particularly the immune-compromised. Many individuals come into contact with opportunistic bacteria and experience no symptoms. Most sources consider these microbes to be normal in the stool. However, they can cause gastroenteritis and inflammation at high levels in vulnerable patients. Symptoms may include diarrhea, loose stools, abdominal pain, or even constipation.
Overgrowth and excessive colonization by opportunistic bacteria may occur when the commensal bacteria are impaired by poor diet, antibiotic use, parasitic infection, or a weakened immune system. When intestinal permeability is present (see zonulin), these microbes could escape the lumen of the gut and infect extraintestinal sites.
ADDITIONAL DYSBIOTIC/OVERGROWTH BACTERIA
- Enterococcus faecalis
- Enterococcus faecium
- Methanobacteriaceae (family)
- Morganella morganii
- Pseudomonas spp.
- Pseudomonas aeruginosa
- Staphylococcus spp.
- Staphylococcus aureus
- Streptococcus spp.
POTENTIAL AUTOIMMUNE TRIGGERS
- Citrobacter spp.
- Citrobacter freundii
- Fusobacterium spp.
- Klebsiella spp.
- Klebsiella pneumoniae
- Mycobacterium avium
- Prevotella copri
- Proteus spp.
- Proteus mirabilis
Fungal organisms are commonly found in the human digestive tract, but fungal overgrowth can cause illness in susceptible individuals. Fungal growth may be localized in the body. For instance, Candida spp. may be high in the large intestine but normal in the small intestine, and vice versa. In a patient with suspected fungal overgrowth, additional tests may be necessary to understand the complete picture of fungal overgrowth. Urinary D-arabinitol or antibodies to Candida are sometimes used.
- Candida albicans
- Candida spp.
- Geotricum spp.
- Microsporidia spp.
- Rhodoturula spp.
- CMV- Cytomegalovirus
- EBV- Epstein Bar Virus
A parasite is an organism that lives and feeds on a host organism at the expense of the host. The GI-MAP tests for pathogenic parasites and protozoa (some of which are non-pathogenic) most commonly occurring in the GI tract. Sources of exposure should be identified and eliminated to prevent reinfection.
- Blastocystis hominis
- Chilomastix mesnelli
- Cyclospora cayetanenensis
- Dientamoeba fragilis
- Endolimax nana
- Entamoeba coli
- Pentatrichomonas hominis
- Ancyclostroma duodenale
- Ascaris lumbricoides
- Necator americanis
- Trichuris trichiura
- Taenia solium/saginada
INTESTINAL HEALTH MARKERS
- Anti-gliadin SIgA
- Occult Blood - FIT
ANTIBIOTIC RESISTANCE GENES
The GI-MAP includes results for detection of antibiotic resistance genes in the microbiome. If an antibiotic resistance gene is present, then that class of antibiotics is designated POSITIVE for antibiotic resistance. A positive result for the presence of resistance genes for a given antibiotic indicates that the antibiotic is not an ideal choice for an antibiotic protocol.
Antibiotic resistance genes apply to all of the microorganisms found in the fecal sample. Since microbes can rapidly share DNA under stress, the presence of antibiotic resistance in any organism is reason enough to avoid that drug class.
Phenotypes | HELOBACTER
Genotypes | UNIVERSAL MICROBIOTA RESISTANCE GENES
UNIVERSAL MICROBIOTA RESISTANCE GENES
Start the GI-MAP Journey Today
Teaming up with us is easy using our Account Setup page. Testing is backed up by scientific literature and uses advanced testing methods that provide reliable quantitative results with clinically-actionable decision points for your patients. (See information below if you're a patient.)
The GI-MAP is the most accurate, comprehensive DNA stool analysis on the market. Become part of our team of practitioners who regularly use it to improve patient outcomes. (See what practitioners are saying about the GI-MAP stool test.)
Our commitment to laboratory medicine is to utilize proven methodologies that are accurate and reliable.
The GI-MAP is always evolving.
The GI-MAP is committed to the using the most advanced technology.
Clinicians are getting phenomenal results from the GI-MAP.
Are You a Patient?
A healthcare practitioner will need to order the test for you. That can be your own doctor, or we can help you find a practitioner in your area.
We know that other companies may offer to sell stool testing directly to you. The GI-MAP is a diagnostic tool and relies on state-of-the-art technology to provide insights into your health. It can be used for patients suffering from serious illnesses, like autoimmune diseases, thyroid diseases, parasitic infections, and Crohn's Disease – to name a few.
These serious health concerns should be treated by a licensed practitioner who can interpret your test results and tailor a treatment plan unique to your specific needs.
Your health is your greatest asset – only entrust it to an expert.
Our transparent patient billing system is easy to use, and we file claims to insurance and Medicare.
Why We're So Passionate about Patient Health
Since the introduction of the GI-MAP, we have received hundreds of messages from practitioners and patients about how a simple stool test (that can be collected in one day), has changed their lives for the better. Ultimately, improved patient outcomes are our goal.
Every test that comes through our door is an opportunity for us to deliver life-changing results to practitioners that are working with patients that need answers. Sometimes those results show that a patient is suffering from multiple parasites. When a gut infection is found it presents an opportunity for the healing journey to begin and for patients to win. And, that's why we do what we do.
Diagnostic Solutions Laboratory is CLIA Certified
In addition to our internal quality control and validation processes, Diagnostic Solutions Laboratory is CLIA certified. CLIA certification ensures that our laboratory meets or exceeds U.S. standards set for laboratory excellence.
- Support item one
- Support item one
- Support item one
The GI-MAP is Constantly Evolving
The Human Microbiome Project began in 2007. Since then, the amount of research about the inhabitants of the gut microbiome and the impact they have on health has expanded exponentially. When new bacterial, commensal, or other organisms of relevance are discovered, we begin working on adding them to the GI-MAP. Our test moves in the same direction as the science that comes out about it does.
Are You a New GI-MAP User?
GI-MAP is Revolutionizing the Comprehensive Stool Analysis
Microscopy and culture-based tests are familiar, but they have limitations with sensitivity, specificity, and identifying anaerobic organisms – that is why almost no peer-reviewed research studies have used microscopy and culture-based testing methods in over 20 years.